trending Market Intelligence /marketintelligence/en/news-insights/trending/lumkhZl6rJtVrXiva97DRg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

G&E Herbal Biotechnology Q4 profit falls YOY

Blog

COVID-19 Impact & Recovery: LCD Outlook for H2 2021

Blog

COVID-19 Impact & Recovery: Technology Outlook for H2 2021

Blog

COVID-19 Impact & Recovery: Financial Industry Outlook for H2 2021

Blog

COVID-19 Impact & Recovery: Credit and Markets Outlook for H2 2021


G&E Herbal Biotechnology Q4 profit falls YOY

G&E Herbal Biotechnology Co. Ltd. said its fourth-quarter normalized net income amounted to 2 Taiwan cents per share, a decline of 63.3% from 5 cents per share in the prior-year period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was NT$1.1 million, a decrease of 63.3% from NT$2.9 million in the prior-year period.

The normalized profit margin dropped to 4.0% from 13.1% in the year-earlier period.

Total revenue climbed 20.8% year over year to NT$27.1 million from NT$22.4 million, and total operating expenses increased 6.7% on an annual basis to NT$28.4 million from NT$26.6 million.

Reported net income fell 63.5% on an annual basis to NT$1.4 million, or 3 cents per share, from NT$3.9 million, or 7 cents per share.

For the year, the company's normalized net income totaled a loss of 15 cents per share, compared with 19 cents per share in the prior year.

Normalized net income was a loss of NT$8.1 million, compared with income of NT$10.3 million in the prior year.

Full-year total revenue declined 29.4% year over year to NT$54.1 million from NT$76.6 million, and total operating expenses rose 8.9% on an annual basis to NT$87.1 million from NT$80.0 million.

The company said reported net income totaled a loss of NT$11.9 million, or a loss of 21 cents per share, in the full year, compared with income of NT$13.7 million, or 25 cents per share, the prior year.

As of March 30, US$1 was equivalent to NT$32.18.